Literature DB >> 23545358

Current approaches for neoadjuvant chemotherapy in breast cancer.

Roisin M Connolly1, Vered Stearns.   

Abstract

Compared to adjuvant chemotherapy, the administration of the same regimen in the neoadjuvant setting provides women with identical improvements in disease free and overall survival. Neoadjuvant chemotherapy may offer benefits to properly selected women such as broadening surgical options and enhancing the likelihood of breast conservation. Assessment of response to neoadjuvant chemotherapy provides women with an individualized estimate of prognosis. For example, a woman who achieves a complete pathological response following neoadjuvant chemotherapy has a very low risk of recurrence compared to a woman with similar tumor characteristics and a large residual disease. In this review we will provide a historical perspective and discuss the aims of neoadjuvant chemotherapy in primary operable breast cancer; as well as appropriate patient selection, treatment strategies, response monitoring, and postoperative care. We will also discuss the attractiveness of this approach to study the mechanism of action of standard and novel agents, and the role of predictive biomarkers of response to treatment and outcomes.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Preoperative chemotherapy; Primary chemotherapy

Mesh:

Year:  2013        PMID: 23545358      PMCID: PMC3758450          DOI: 10.1016/j.ejphar.2013.02.057

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  53 in total

1.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

2.  Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

Authors:  Ian E Smith; Mitch Dowsett; Stephen R Ebbs; J Michael Dixon; Anthony Skene; J-U Blohmer; Susan E Ashley; Stephen Francis; Irene Boeddinghaus; Geraldine Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

3.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

Authors:  B Fisher; A Brown; E Mamounas; S Wieand; A Robidoux; R G Margolese; A B Cruz; E R Fisher; D L Wickerham; N Wolmark; A DeCillis; J L Hoehn; A W Lees; N V Dimitrov
Journal:  J Clin Oncol       Date:  1997-07       Impact factor: 44.544

4.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Authors:  H M Kuerer; L A Newman; T L Smith; F C Ames; K K Hunt; K Dhingra; R L Theriault; G Singh; S M Binkley; N Sneige; T A Buchholz; M I Ross; M D McNeese; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

5.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.

Authors:  D M Sataloff; B A Mason; A J Prestipino; U L Seinige; C P Lieber; Z Baloch
Journal:  J Am Coll Surg       Date:  1995-03       Impact factor: 6.113

6.  Presence of a growth-stimulating factor in serum following primary tumor removal in mice.

Authors:  B Fisher; N Gunduz; J Coyle; C Rudock; E Saffer
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

7.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Ann Brown; Roy Smith; Eleftherios P Mamounas; Bernard Fisher; Richard Margolese; Heather Theoret; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2003-10-14       Impact factor: 44.544

8.  Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

Authors:  B Chevallier; H Roche; J P Olivier; P Chollet; P Hurteloup
Journal:  Am J Clin Oncol       Date:  1993-06       Impact factor: 2.339

9.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

Authors:  M Ayers; W F Symmans; J Stec; A I Damokosh; E Clark; K Hess; M Lecocke; J Metivier; D Booser; N Ibrahim; V Valero; M Royce; B Arun; G Whitman; J Ross; N Sneige; G N Hortobagyi; L Pusztai
Journal:  J Clin Oncol       Date:  2004-05-10       Impact factor: 44.544

10.  [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].

Authors:  H P Sinn; H Schmid; H Junkermann; J Huober; G Leppien; M Kaufmann; G Bastert; H F Otto
Journal:  Geburtshilfe Frauenheilkd       Date:  1994-10       Impact factor: 2.915

View more
  8 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators.

Authors:  Martin D Pickles; Martin Lowry; David J Manton; Lindsay W Turnbull
Journal:  Eur Radiol       Date:  2014-11-26       Impact factor: 5.315

3.  Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.

Authors:  Nimita Dave; Lionel M L Chow; Gary A Gudelsky; Kathleen LaSance; Xiaoyang Qi; Pankaj B Desai
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

4.  Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.

Authors:  Nóra Igaz; Péter Bélteky; Dávid Kovács; Csaba Papp; Andrea Rónavári; Diána Szabó; Attila Gácser; Zoltán Kónya; Mónika Kiricsi
Journal:  Int J Nanomedicine       Date:  2022-07-14

5.  Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy--the SpheroNEO study.

Authors:  Kathrin Halfter; Nina Ditsch; Hans-Christian Kolberg; Holger Fischer; Tanja Hauzenberger; Franz Edler von Koch; Ingo Bauerfeind; Gunter von Minckwitz; Ilona Funke; Alexander Crispin; Barbara Mayer
Journal:  BMC Cancer       Date:  2015-07-15       Impact factor: 4.430

6.  Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.

Authors:  Prihantono Prihantono; Mochammad Hatta; Christian Binekada; Daniel Sampepajung; Haryasena Haryasena; Berti Nelwan; Andi Asadul Islam; Andi Nilawati Usman
Journal:  J Oncol       Date:  2017-10-31       Impact factor: 4.375

7.  Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Authors:  Natasha K Brockwell; Jai Rautela; Katie L Owen; Linden J Gearing; Siddhartha Deb; Kate Harvey; Alex Spurling; Damien Zanker; Chia-Ling Chan; Helen E Cumming; Niantao Deng; Jasmine M Zakhour; Hendrika M Duivenvoorden; Tina Robinson; Marion Harris; Michelle White; Jane Fox; Corinne Ooi; Beena Kumar; Jacqui Thomson; Nicole Potasz; Alex Swarbrick; Paul J Hertzog; Tim J Molloy; Sandra O' Toole; Vinod Ganju; Belinda S Parker
Journal:  NPJ Precis Oncol       Date:  2019-08-29

Review 8.  Reuse of Molecules for Glioblastoma Therapy.

Authors:  Abigail Koehler; Aniruddha Karve; Pankaj Desai; Jack Arbiser; David R Plas; Xiaoyang Qi; Renee D Read; Atsuo T Sasaki; Vaibhavkumar S Gawali; Donatien K Toukam; Debanjan Bhattacharya; Laura Kallay; Daniel A Pomeranz Krummel; Soma Sengupta
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.